Standaert Baudouin, Rappuoli Rino
Health Economics, GSK, Wavre, Belgium.
Research & Development, GSK, Siena, Italy.
J Mark Access Health Policy. 2017 Aug 31;5(1):1335162. doi: 10.1080/20016689.2017.1335162. eCollection 2017.
Since we were born, we all take preventative actions to avoid unpredictable adverse conditions. Some actions are done automatically. Others require a conscious choice , either for personal or social benefit. A distinction can therefore be drawn between non-active and active prevention, and between individual and social prevention. Active prevention requires making a choice in time, effort, and cost. We call it an economic choice. Vaccines belong to the group of active and social prevention. Because a vaccination program is an economic social choice, how should it be valued, and what cost should we pay for? To date, the economic evaluations developed for treatment have been applied to vaccines. However, over 25 different characteristics differentiate vaccines from treatment. For example, the benefit of vaccination is measured at the population level not at the individual level, the main effect of prevention is societal and not an individual-based gain only, and the biggest hurdle to implement a new vaccine is the initial budget investment and not so much its estimated 'value for money'. This makes the current application of incremental cost-utility analysis difficult for vaccines for a comprehensive evaluation. New approaches may be needed to capture the full economic benefit of vaccines..
自出生以来,我们都会采取预防措施以避免不可预测的不利状况。有些行动是自动进行的,而其他行动则需要有意识地做出选择,无论是为了个人利益还是社会利益。因此,可以区分消极预防和积极预防,以及个体预防和社会预防。积极预防需要在时间、精力和成本方面做出选择。我们将其称为经济选择。疫苗属于积极和社会预防的范畴。由于疫苗接种计划是一种经济社会选择,那么应该如何对其进行评估,我们又应该为此付出怎样的成本呢?迄今为止,为治疗开发的经济评估方法已应用于疫苗。然而,疫苗与治疗有超过25种不同的特征。例如,疫苗接种的益处是在人群层面衡量的,而不是在个体层面;预防的主要效果是社会性的,而不仅仅是基于个体的收益;实施新疫苗的最大障碍是初始预算投资,而不是其估计的“性价比”。这使得目前应用增量成本效用分析来全面评估疫苗变得困难。可能需要新的方法来获取疫苗的全部经济效益。